title: Four-factor prothrombin complex concentrate versus plasma for urgent vitamin K antagonist reversal: new evidence.
abstract: Vitamin K antagonist (VKA) therapy is a mainstay of treatment for patients at risk of thromboembolic events. Despite widespread use, a major limitation of VKA therapy is the substantial risk of serious bleeding complications, which often require rapid reversal of anticoagulation. A recent randomized multicenter comparison between a 4-factor prothrombin complex concentrate (4F-PCC) and plasma in patients with acute major bleeding has provided important new evidence of the benefit of 4F-PCC over plasma for urgent VKA reversal.
authors.affiliation: Division of Transfusion Medicine and Hemostasis, Department of Pathology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9234, USA. Electronic address: ravi.sarode@utsouthwestern.edu.
authors.forename: Ravi
authors.initials: R
authors.lastname: Sarode
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects* / Q000737:chemistry; D001779:Blood Coagulation Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D016913:Blood Component Transfusion; D003131:Combined Modality Therapy; D019317:Evidence-Based Medicine; D006470:Hemorrhage / Q000139:chemically induced / Q000188:drug therapy* / Q000628:therapy; D006490:Hemostatics / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007262:Infusions, Intravenous; D010949:Plasma; D016032:Randomized Controlled Trials as Topic; D014812:Vitamin K / Q000037:antagonists & inhibitors* / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D001779:Blood Coagulation Factors; D006490:Hemostatics; D014812:Vitamin K; C025667:prothrombin complex concentrates
keywords: Anticoagulants; Hemorrhage; Plasma; Prothrombin complex concentrates; Vitamin K antagonist